A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody.
about
Possible role of a cell surface carbohydrate in evolution of resistance to viral infections in old world primatesNo biological evidence of XMRV in blood or prostatic fluid from prostate cancer patientsThe Galalpha1,3Galbeta1,4GlcNAc-R (alpha-Gal) epitope: a carbohydrate of unique evolution and clinical relevanceNatural anti-carbohydrate antibodies contributing to evolutionary survival of primates in viral epidemics?Disordered regulation of coagulation and platelet activation in xenotransplantation.The alphaGal epitope of the histo-blood group antigen family is a ligand for bovine norovirus Newbury2 expected to prevent cross-species transmission.Host cell glycosylation of viral glycoproteins--a battlefield for host defence and viral resistance.The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent.Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons.Progress with retroviral gene vectors.Specificity and prevalence of natural bovine anti-alpha galactosyl (Galalpha1-6Glc or Galalpha1-6Gal) antibodiesAn approach to the control of disease transmission in pig-to-human xenotransplantation.No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected.Human CD59 incorporation into porcine endogenous retrovirus particles: implications for the use of transgenic pigs for xenotransplantationClearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complementEffects of innate immunity on herpes simplex virus and its ability to kill tumor cells.Hepatocellular carcinoma-specific immunotherapy with synthesized α1,3- galactosyl epitope-pulsed dendritic cells and cytokine-induced killer cellsStructural and functional anatomy of the globular domain of complement protein C1q.Cell targeting in anti-cancer gene therapyA stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypesPlasmoviruses: nonviral/viral vectors for gene therapy.Barriers to Infection of Human Cells by Feline Leukemia Virus: Insights into Resistance to Zoonosis.Gal/non-Gal antigens in pig tissues and human non-Gal antibodies in the GalT-KO era.Reduced sensitivity to human serum inactivation of enveloped viruses produced by pig cells transgenic for human CD55 or deficient for the galactosyl-alpha(1-3) galactosyl epitope.CD55 limits sensitivity to complement-dependent cytolysis triggered by heterologous expression of α-gal xenoantigen in colon tumor cells.Evaluation of the Galalpha1-3Gal epitope as a host modification factor eliciting natural humoral immunity to enveloped viruses.Sensitization of rhabdo-, lenti-, and spumaviruses to human serum by galactosyl(alpha1-3)galactosylationIntracellularly expressed single-domain antibody against p15 matrix protein prevents the production of porcine retroviruses.Natural protection from zoonosis by alpha-gal epitopes on virus particles in xenotransmission.PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum.Generation of stable retrovirus packaging cell lines after transduction with herpes simplex virus hybrid amplicon vectors.Viral gene delivery.Development of a suspension packaging cell line for production of high titre, serum-resistant murine leukemia virus vectors.Human serum-resistant retroviral vector particles from galactosyl (alpha1-3) galactosyl containing nonprimate cell lines.Complement and anti-alpha-galactosyl natural antibody-mediated inactivation of murine retrovirus occurs in adult serum but not in umbilical cord serum.Generation of monoclonal antibodies against the Galβ1-4Gal epitope: a key tool in studies of species-specific glycans expressed in fish, amphibians and birds.Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.Infection and xenotransplantation. Developing strategies to minimize risk.Induction of complement attack on human cells by Gal(alpha1,3)Gal xenoantigen expression as a gene therapy approach to cancer.Distribution of retroviral vectors and vector producer cells using two routes of administration in rats.
P2860
Q28675345-219C7D74-FB3D-4F64-8849-963E1F922DB9Q28729917-5A5652CC-8795-4614-A2D2-8DE96BA945E0Q28755302-BA389B04-B9AD-4420-BD2A-93A3EDCD68E7Q30248270-1D692D24-8DD1-4DCA-B898-184736B767BDQ33334538-95801E0F-E9D8-4B2B-AB13-B895EB7114ECQ33478403-BEA9D0D7-45AC-4588-B7C4-0EFF8D6B1662Q33538414-D0067358-E261-4DF1-B9A9-D909AC55B5A8Q33817487-34296D3B-783E-4753-9DEA-2EC24336B4BBQ33825579-891FBAC3-35E2-4433-A39F-BFC6BAC8B87AQ33920752-8FD0B213-D3DC-4C23-A33C-96F33989FB15Q33998415-1AFCFA8F-2667-49BA-9473-17E3032373DCQ34015350-47D4FE85-4CAA-4381-9B73-9C6580EFE3A9Q34188640-1D5F0376-3E5B-44F9-A462-48464FBC37F0Q34331007-4C438BE1-9388-4BB5-B7C7-01B8BE2732E0Q34597583-189273C0-A503-455D-BBB5-211C4993CBEEQ35131235-BC34E9C7-423C-43AC-9D98-9B0684DD3B39Q35638775-675646DA-3357-4C8F-B276-C381D2480667Q35896873-36D998DB-5807-4E0F-A0C4-F9309BC7ED4EQ36222776-31AA9828-28DC-4186-B6F0-30D6206FA384Q37251604-29C0F4E9-4B8A-4E27-8FFC-1FBAB7E21E5AQ37631837-15380173-EA9C-44C6-8E48-15F000BBA69FQ37642870-6CCD2FA5-3494-4FBB-8F78-FD525369ADB2Q37919109-411A5A70-22AD-4919-BA28-F56DAE3F9C6FQ38341233-E6B6136B-3CFF-4B1C-8CBF-F880419B594BQ39001370-1388C28F-FE5F-4913-8188-9F721F713F34Q39580367-39DC8D44-E50A-4B5A-B791-CE0738053B96Q39880641-25C54287-D1E6-45D5-8CDA-F0CB2DD18B92Q40132922-9D6BF893-2FEF-4668-B11F-B9EF34811AECQ40155038-F6D7FC0F-DF7C-40FC-8919-23FFF5E9A004Q40674636-E2372DCB-B6DE-445B-91D5-95665A8876C3Q40718975-E9045170-772B-4DA7-BB9B-6C1C16FD0597Q40732042-9946A244-D6BF-4D5D-AD68-860013F2F2B3Q40797068-F1648105-9EF8-4E31-9E95-13BECDAAFF43Q40931998-C303375F-11BB-4A57-9633-1196C963B463Q40952196-05412BEA-5224-4716-B50E-8937F98CD7CEQ42716094-E8A2CF92-1D93-4738-BA5A-3A651D15994CQ44368424-B58341D2-89BB-4B7E-B952-DE15DF8029E1Q44825658-2D7D440D-4D19-4425-B819-40102A685CF4Q45861534-270691D2-F1AE-47BD-A9D5-1D66FB814A8CQ45861885-EF25910D-2DBE-462A-A1C8-8AEB866BED95
P2860
A novel mechanism of retrovirus inactivation in human serum mediated by anti-alpha-galactosyl natural antibody.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
1995年學術文章
@zh
1995年學術文章
@zh-hant
name
A novel mechanism of retroviru ...... a-galactosyl natural antibody.
@ast
A novel mechanism of retroviru ...... a-galactosyl natural antibody.
@en
type
label
A novel mechanism of retroviru ...... a-galactosyl natural antibody.
@ast
A novel mechanism of retroviru ...... a-galactosyl natural antibody.
@en
prefLabel
A novel mechanism of retroviru ...... a-galactosyl natural antibody.
@ast
A novel mechanism of retroviru ...... a-galactosyl natural antibody.
@en
P2093
P2860
P356
P1476
A novel mechanism of retroviru ...... a-galactosyl natural antibody.
@en
P2093
Rollins SA
Sandrin MS
Springhorn JP
Squinto SP
P2860
P304
P356
10.1084/JEM.182.5.1345
P407
P577
1995-11-01T00:00:00Z